Comparative effectiveness of odronextamab monotherapy real-world systemic therapies in R/R follicular lymphoma.
1/5 보강
To contextualize results from the single-arm ELM-2 study of odronextamab (CD20 × CD3 bispecific antibody) in relapsed/refractory (R/R) follicular lymphoma (FL) ( = 128), a comparison was conducted t
- 95% CI 1.98-7.11
APA
Bachy E, Harnett J, et al. (2026). Comparative effectiveness of odronextamab monotherapy real-world systemic therapies in R/R follicular lymphoma.. Leukemia & lymphoma, 67(4), 907-918. https://doi.org/10.1080/10428194.2026.2619500
MLA
Bachy E, et al.. "Comparative effectiveness of odronextamab monotherapy real-world systemic therapies in R/R follicular lymphoma.." Leukemia & lymphoma, vol. 67, no. 4, 2026, pp. 907-918.
PMID
41736495 ↗
Abstract 한글 요약
To contextualize results from the single-arm ELM-2 study of odronextamab (CD20 × CD3 bispecific antibody) in relapsed/refractory (R/R) follicular lymphoma (FL) ( = 128), a comparison was conducted third-line or later systemic therapies used in the real world (3L + RWST) in FLORA, a multinational, noninterventional study ( = 83; 100 lines of therapy). After weighting, objective response rate (80.5 52.7%; odds ratio [OR], 3.75 [95% CI, 1.98-7.11]), complete response rate (73.4 33.6%; OR, 5.39 [95% CI, 2.76-10.53]), median (months) progression-free survival (20.7 11.5; hazard ratio [HR], 0.76 [95% CI, 0.46-1.24]), event-free survival (19.5 7.6; HR, 0.52 [95% CI, 0.36-0.77]), overall survival (not reached 26.2; HR, 0.60 [95% CI, 0.37-0.97]), and time to next treatment or death (40.4 9.7; HR, 0.49 [95% CI, 0.33-0.72]) favored odronextamab 3L + RWST. Despite FLORA's limited sample size, these data further support odronextamab monotherapy for 3L + R/R FL.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Lymphoma
- Follicular
- Male
- Female
- Middle Aged
- Aged
- Antibodies
- Bispecific
- Adult
- Antineoplastic Combined Chemotherapy Protocols
- Drug Resistance
- Neoplasm
- Treatment Outcome
- Antineoplastic Agents
- Immunological
- Neoplasm Recurrence
- Local
- 80 and over
- Bispecific antibody
- comparative effectiveness
- external control arm
- follicular lymphoma
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.